Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Outlook Therapeutics Inc OTLK

Healthcare Biotechnology
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD)... see more

Recent & Breaking News (NDAQ:OTLK)

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)

PR Newswire December 4, 2023

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your Rights - OTLK

Accesswire December 3, 2023

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

PR Newswire December 3, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire December 3, 2023

Outlook Ongoing Deadline Alert

Newsfile December 3, 2023

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook Lawsuit - OTLK

Accesswire December 3, 2023

OTLK Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 3, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $100,000 to Contact the Firm

Accesswire December 3, 2023

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire December 2, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK

Accesswire December 2, 2023

ROSEN, LEADING INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Newsfile December 2, 2023

INVESTOR ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - OTLK

Accesswire December 1, 2023

OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire December 1, 2023

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 1, 2023

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook Lawsuit - OTLK

Accesswire December 1, 2023

OTLK Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 1, 2023

INVESTOR ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

Accesswire December 1, 2023

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire December 1, 2023

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

TheNewsWire November 30, 2023

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

Accesswire November 30, 2023